Adventrx Pharmaceuticals plans public sale of common stock, warrants

Deal with 15% greenshoe to finance development of product candidates

By Devika Patel

Knoxville, Tenn., Nov. 10 - Adventrx Pharmaceuticals, Inc. said it will price a public offering of stock and warrants with a 45-day, 15% greenshoe.

Rodman & Renshaw, LLC is the sole bookrunning manager.

Proceeds will be used for development of the company's lead product candidates and general corporate purposes.

Adventrx is a San Diego-based biopharmaceutical company focused on developing proprietary product candidates for diseases such as sickle cell disease and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.